April 23, 2026 – The 10th All Blossom Conference, hosted by the Zhejiang Provincial Committee of the China National Democratic Construction Association (Minjian), the Zhejiang Chamber of Commerce, and the China Investment Development Promotion Association, kicked off grandly in Hangzhou.

During the event, Hangzhou Entrepreneurship & Venture Association, in collaboration with Welian and Bank of Hangzhou, officially released the 2026 Hangzhou Unicorn and Emerging Unicorn Enterprises List, highlighting the robust and thriving industrial ecosystem in Hangzhou.

Driven by its strong technical capabilities and steady development, Westlake Pharma has once again been named a Hangzhou Emerging Unicorn.

The sectoral distribution of this year’s Emerging Unicorns resonates with Hangzhou’s industrial layout: the Life and Health sector leads the list with a 28.57% share; the New Generation Information Technology sector follows with 18.89%; and Artificial Intelligence and Embodied AI ranks third with 12.11%. Together, these three sectors account for approximately 60%, serving as the core engines driving the development of new quality productive forces in Hangzhou.

As Hangzhou’s industrial ecosystem continues to mature—particularly with the in-depth advancement of the new quality productive forces strategy—the structural landscape of the listed companies has evolved significantly, marking a transition from being consumer-ledin 2018 to being hard-tech driven in 2026.

Westlake Pharma is a technology commercialization enterprise originating from Westlake University and Westlake Laboratory. Since its establishment in 2020, the company has been consistently focused on the research and development of novel medicines.

Adopting a forward-looking perspective, the company integrates Artificial Intelligence with deep multi-disciplinary expertise to revolutionize the R&D paradigm, effectively addressing the industry-wide challenges of high investment and long development cycles.

Our proprietary AI-Driven Precision Drug Design platform, WAND (Westlake AI for Novel Drug, WAND）, has been fully deployed across our internal pipelines, significantly enhancing the team's operational efficiency.

Currently, the company focus on two core areas: oncology and infectious diseases. Its first novel drug candidate has successfully completed clinical trials, with other pipeline projects progressing steadily.

This list serves as both a witness to and an enabler of enterprise growth in Hangzhou. Between 2018 and 2026, the number of unicorn companies in Hangzhou grew from 26 to 48, while the number of Emerging Unicorns surged from 105 to 413. Since the list was first published, a total of 38 companies have successfully gone public.

This marks the fourth year that Westlake Pharma has been included in the Hangzhou Emerging Unicorn Enterprises list. Moving forward, Westlake Pharma will remain dedicated to the R&D of novel medicines, contributing to Hangzhou’s goal of building a premier hub for the Life and Health industry and further empowering the development of new quality productive forces.